Patents Issued in January 17, 2019
-
Publication number: 20190015311Abstract: An oil-based eyelash cosmetic including 3 to 40% by mass of an oil-soluble film forming agent (A), 0.1 to 10% by mass of a nonionic surfactant having an HLB value of 7 to 10 (B), 20 to 70% by mass of a volatile oil (C) and 0.5 to 30% by mass % of a nonvolatile oil (D), wherein the ratio of the component (A) and the component (D) [(A)/(D) (mass ratio)] is 0.7/1 to 5.8/1. When a solid oil having a melting point of 50° C. or higher is contained, the amount thereof is 10% by mass or less. The cosmetic exhibits excellent removability by warm water as well as excellent curling effect and long-lasting performance of cosmetic effect such as water resistance peculiar to conventional oil-based eyelash cosmetics.Type: ApplicationFiled: January 13, 2017Publication date: January 17, 2019Applicant: JO Cosmetics Co., Ltd.Inventors: Mizuyo INOUE, Yumi TOMIYAMA, Hazuki UCHIDA, Akihiro NAKANO, Satoshi HARAMIZU
-
Publication number: 20190015312Abstract: A cosmetic formulation can include a salt based cosmetic astringent and an active peptide. The salt based cosmetic astringent can form at least about 0.1% by total weight of the cosmetic formulation. The active peptide can include at least one of (i) a dipeptide including Arginine and Tyrosine and (ii) an oligopeptide with at least four amino acids.Type: ApplicationFiled: December 29, 2015Publication date: January 17, 2019Inventors: YoenJung Lee, Scott W. Wenzel, Stacy A. Mundschau
-
Publication number: 20190015313Abstract: Disclosed herein is mucin-coated silica, compositions comprising the same, and methods of promoting the aggregation and/or clearance of oral bacteria using such compositions.Type: ApplicationFiled: December 30, 2016Publication date: January 17, 2019Applicant: Colgate-Palmolive CompanyInventors: Carlo DAEP, Michael FITZGERALD, Ekta MAKWANA, Peter R. HILLIARD, JR., Shamim ANSARI, Robert D'AMBROGIO
-
Publication number: 20190015314Abstract: The present invention is relating to a cosmetic composition comprising: -at least 2% by weight, with respect to the weight of the composition, of alkylcellulose, the alkyl residue of which comprises between 2 and 6 carbon atoms, preferably between 2 and 3, -at least one non-volatile polar hydrocarbon first oil, -at least 20% by weight, with respect to the weight of the composition, of at least one second oil, incompatible with the first oil or oils, chosen from non-volatile silicone oils, from non-volatile fluorinated oils, or their combinations, -optionally at least one non-volatile third oil, different from the first oil or oils, chosen from polar or non-polar hydrocarbon oils, silicone oils different from the second oil or oils, phenylated oils not comprising a dimethicone fragment, or their mixtures, -less than 5% by weight of water, with respect to the weight of the composition. The composition can comprise at least one wax.Type: ApplicationFiled: December 15, 2016Publication date: January 17, 2019Applicant: L'OREALInventors: Florence LAHOUSSE, Emilie HENIN
-
Publication number: 20190015315Abstract: The present invention provides sunscreen composition comprising a hydrophobically modified polyurethane, a taurate copolymer, and glyceryl stearate. This composition has surprisingly light aesthetics while providing excellent UV protection.Type: ApplicationFiled: July 13, 2017Publication date: January 17, 2019Inventors: Cinthia Zanatta, Jeffrey Daniel Martin
-
Publication number: 20190015316Abstract: The present disclosure relates to cosmetic agents for temporary deformation of keratinous fibers, particularly human hair, which contain completely non-neutralized anionic polymer and at least one special ester and/or siloxane compound. These cosmetic agents have extremely good moisture resistance and washability. The present disclosure also relates to the use of these cosmetic agents and a method for temporary deformation of keratinous fibers using these agents.Type: ApplicationFiled: June 28, 2018Publication date: January 17, 2019Applicant: Henkel AG & Co. KGaAInventors: Thorsten Knappe, Tim Bethge, Thea Kroehnke
-
Publication number: 20190015317Abstract: The present invention provides sunscreen composition comprising a hydrophobically modified polyurethane, a viscosity increasing polymer, and glyceryl stearate. This composition has surprisingly light aesthetics while providing excellent UV protection.Type: ApplicationFiled: July 12, 2018Publication date: January 17, 2019Inventors: Cinthia Zanatta, Jeffrey Daniel Martin, Alice Aparecida Consul de Moraes
-
Publication number: 20190015318Abstract: The present invention provides an emulsified cosmetic, including: an anionic acryl silicone copolymer (A) having an acryl chain as the main chain, the copolymer including, as monomer units, (I) 1 to 30% by mass of a polymerizable hydrophilic monomer having carboxylic acid, phosphoric acid, or sulfonic acid neutralized with a base, and (II) 10% by mass or more of a silicone macromonomer represented by the following general formula (1), or a silicone dendron group-containing polymerizable monomer; an oil material (B); and water (C). Accordingly, the present invention provides an emulsified cosmetic having excellent emulsification stability and non-stickiness.Type: ApplicationFiled: February 24, 2017Publication date: January 17, 2019Applicant: SHIN-ETSU CHEMICAL CO., LTD.Inventor: Hiroyuki MORIYA
-
Publication number: 20190015319Abstract: The present disclosure relates to a method for delivering a mucoadhesive composition to the oral cavity of a subject. The mucoadhesive composition comprises one or more active agents, a mucoadhesive polymer, and water. The present disclosure is further related to a method for treating a disease, disorder, or condition, such as pharyngitis, aphthous stomatitis (canker sore), bacterial infection, radiation-induced mucositis, fibromyalgia, and diabetes, comprising administering the mucoadhesive composition to the oral cavity of a subject. The present disclosure is also related a mucoadhesive composition comprising one or more active agents, a mucoadhesive polymer, and water.Type: ApplicationFiled: July 17, 2018Publication date: January 17, 2019Inventor: William L. PRIDGEN
-
Publication number: 20190015320Abstract: The invention relates to the pharmaceutical industry, particularly to the pharmaceutical industry related to drugs comprising biomacromolecules, or biopharmaceuticals. Even more particularly, the invention relates to a pharmaceutical form comprising biomacromolecules such as lymphokines, hormones, haematopoietic factors, growth factors, antibodies, enzymes, inhibitors, vaccines, and DNA or RNA derivatives. The invention provides a pharmaceutical form comprising biomacromolecules and a method for producing same based on inkjet printing using inks formed by nanosystems comprising the biomacromolecule(s), the drug or biopharmaceutical being administered orally.Type: ApplicationFiled: January 6, 2017Publication date: January 17, 2019Inventors: Javier MORALES, Miguel MONTENEGRO, Felipe CAMPANO
-
Publication number: 20190015321Abstract: An oral dosage form to deliver diphenhydramine through the sublingual or buccal mucosa. The oral dosage form can contain diphenhydramine, or a pharmaceutically acceptable salt thereof, a permeability enhancer, and a buffering agent. The buffering agent can achieve a pH of about 7.0 to about 8.0. The diphenhydramine can completely dissolve within about 2 minutes.Type: ApplicationFiled: August 30, 2018Publication date: January 17, 2019Inventors: Richard John Dansereau, Brian Laster, Erin Swigart, Ashraf Traboulsi
-
Publication number: 20190015322Abstract: A method and system to prevent sore throat infections in humans includes the administration of an active ingredient to a site on the mucus membranes of the throat of a human that inhibits adherence and promotes desorption of S. pyogenes to soft tissue surfaces, such as the pharyngeal and oral mucosa of a human. A mucoadhesive strip having a surface topography that resists bioadhesion of undesired bacteria that are typically present in a human's mouth is preferably employed and that has one or more encapsulated agents selected from the group consisting of an antibiotic; lactic acid bacteria; S. pyogenes modified by a CRISPR-Cas system to reduce one or more virulence factors; and a breath mint solution.Type: ApplicationFiled: September 20, 2018Publication date: January 17, 2019Inventors: Joseph E. Kovarik, Katherine Rose Kovarik
-
Publication number: 20190015323Abstract: Drug products adapted for nasal delivery, comprising a pre-primed device filled with a pharmaceutical composition comprising an opioid receptor antagonist, are provided. Methods of treating opioid overdose or its symptoms with the inventive drug products are also provided.Type: ApplicationFiled: September 14, 2018Publication date: January 17, 2019Inventors: Fintan Keegan, Robert Gerard Bell, Roger Crystal, Michael Brenner Weiss
-
Publication number: 20190015324Abstract: The present document describes a buccal delivery dosage form for administration of an active ingredient, including pharmaceutically, pharmacologically, or biologically active ingredients, in the mouth of a subject. The buccal delivery dosage form by-passes the gastrointestinal tract metabolism. The buccal delivery dosage form may comprise chemical permeation enhancers, excipients, texture modulators, and active ingredients.Type: ApplicationFiled: September 18, 2018Publication date: January 17, 2019Applicant: Technologies Khloros Inc.Inventor: Marc PURCELL
-
Publication number: 20190015325Abstract: Provided are a composite liquid pharmaceutical composition and a preparation method thereof, wherein the composite liquid pharmaceutical composition includes a Hedera helix leaf extract and a dry powder of a mixture including a Pelargonium sidoides extract and maltodextrin.Type: ApplicationFiled: January 11, 2017Publication date: January 17, 2019Inventors: Kyoung Rak KIM, Hong Sik MOON, Tae Wook KIM, Sung Jun KIM, Se Mi YU, Yeong Cheol YOON, Jong Hoon KIM
-
Publication number: 20190015326Abstract: The invention provides a novel bioavailability enhancement oral solid dosage form composition and process that enhances the solubility of all poorly soluble drug substances irrespective of their physicochemical properties. The composition comprising a drug substance, at least one solid hydrophilic polymer, at least one high boiling liquid, at least one emulsifier, at least one anti-nucleating agent, and at least one anti-adherent, and the manufacturing process utilizes a high intensity mixer with counter-rotating or co-rotating screw elements.Type: ApplicationFiled: July 11, 2018Publication date: January 17, 2019Inventors: Isaac Ghebre-Sellassie, Hibreniguss Terefe
-
Publication number: 20190015327Abstract: A pharmaceutical composition comprising a lipid component, an amphiphilic emulsifier, a polar liquid carrier, and one or more electrolytes, where the amphiphilic emulsifier forms lipid carrying micelles or liposomes having a lipophilic core comprising the lipid component in the polar liquid carrier, and the micelles or liposomes have an average diameter between 90 nm and 120 nm and are stable for at least 4 weeks at room temperature. The pharmaceutical composition is free of hemoglobin and fluorocarbon and can be used for treating conditions related to lack of blood supply including but not limited to restoring normal cardiac rhythm after cardiac arrest or arrhythmia and to raise the blood pressure and correct hypovolemia.Type: ApplicationFiled: September 14, 2016Publication date: January 17, 2019Inventor: Cuthbert O. SIMPKINS
-
Publication number: 20190015328Abstract: The present invention provides bis-polymer lipid-peptide conjugates containing a hydrophobic block and headgroup containing a helical peptide and two polymer blocks. The conjugates can self-assemble to form helix bundle subunits, which in turn assemble to provide micellar nanocarriers for drug cargos and other agents. Particles containing the conjugates and methods for forming the particles are also disclosed.Type: ApplicationFiled: April 24, 2018Publication date: January 17, 2019Inventors: Ting Xu, He Dong, Jessica Shu, Nikhil Dube
-
Publication number: 20190015329Abstract: The present invention relates to a formulation comprising a primary surfactant, a tocol phosphate, water, an active agent, and optionally an oil, wherein the active agent and/or the optional oil comprises a hydrophobic phase.Type: ApplicationFiled: December 9, 2016Publication date: January 17, 2019Inventor: Mahmoud El-Tamimy
-
Publication number: 20190015330Abstract: Provided herein are methods and compositions for the delivery of bioactive compounds to a cell, tissue, or physiological site. The compositions comprise delivery system complexes comprising liposomes encapsulating a biodegradable ionic precipitate having incorporated therein a bioactive compound and delivery system complexes comprising a biodegradable ionic precipitate ionically bound to a surrounding lipid bilayer, wherein the biodegradable ionic precipitate comprises a bioactive compound. Also provided herein are methods for the treatment of a disease or an unwanted condition in a subject, wherein the methods comprise administering the delivery system complexes comprising bioactive compounds that have therapeutic activity against the disease or unwanted condition to the subject.Type: ApplicationFiled: April 9, 2018Publication date: January 17, 2019Inventors: Leaf Huang, Jun Li
-
Publication number: 20190015331Abstract: Disclosed herein are compositions comprising isolated exosomes, for instance exosomes wherein at least 20% of the exosomes comprise SDC2, methods of isolation, and methods of use.Type: ApplicationFiled: January 13, 2017Publication date: January 17, 2019Inventors: Stephen J. ELLIMAN, Jack Kavanaugh, Larry COUTURE
-
Publication number: 20190015332Abstract: The present disclosure provides methods of treating breast cancer, including triple negative breast cancer. The methods disclosed herein comprise administering a cationic liposomal formulation containing one or more cationic lipids and a taxane to a subject in need thereof. The methods also include administering one or more non-liposomal formulations including one or more active agents.Type: ApplicationFiled: December 28, 2016Publication date: January 17, 2019Applicants: SynCore Biotechnology Co. Ltd., CanCap Pharmaceutical Ltd.Inventors: Sih-Ting Lin, Hsin-Wei Teng, Hui-Yuan Tseng
-
Publication number: 20190015333Abstract: Vesicular stomatitis virus glycoprotein (VSVG) can both load protein cargo onto exosomes and increase their delivery ability via a pseudotyping mechanism. By fusing a set of fluorescent and luminescent reporters with VSVG, we show the successful targeting and incorporation of VSVG fusions into exosomes by gene transfection and fluorescence tracking. VSVG pseudotyping of exosomes does not affect the size or distributions of the exosomes, and both the full-length VSVG and the VSVG without the ectodomain integrate into the exosomal membrane, suggesting that the ectodomain is not required for protein loading. Finally, exosomes pseudotyped with full-length VSVG are internalized by multiple-recipient cell types to a greater degree compared to exosomes loaded with VSVG without the ectodomain, confirming a role of the ectodomain in cell tropism.Type: ApplicationFiled: July 12, 2018Publication date: January 17, 2019Inventors: Biao Lu, Conary Meyer, Joseph Losacco, Zachary Stickney
-
Publication number: 20190015334Abstract: Compositions and methods for making and using proliposomal and liposomal formulations of chemotherapeutic agents are disclosed. The proliposomal and liposomal formulations of chemotherapeutics, as well as medicaments and dosage forms that include such formulations, can be used with treatment regimens for bladder cancer and urothelial cancer. Hence, the formulations, medicaments, and dosage forms of the invention are suitable to treat bladder cancers by intravesical administration and to treat urothelial cancers. The formulations according to the invention include (a) a taxane (e.g., paclitaxel, docetaxel) or cisplatin, (b) a first phospholipid, dipalmitoyl phosphatidylcholine (DMPC), and (c) a second phospholipid, dimyrsityl phosphatidyl glycerol sodium (DMPG). The proliposomal formulations form liposomes upon contact with an aqueous vehicle.Type: ApplicationFiled: January 9, 2017Publication date: January 17, 2019Inventors: Guru V. BETAGERI, Natarajan VENKATESAN, Michael G. OEFELEIN
-
Publication number: 20190015335Abstract: Compositions for targeted delivery of a protective agent to the liver, and systems and methods for administering the compositions are described. When administered prior to or in combination with one or more chemotherapeutic agents, the compositions containing the protective agent protect the liver without adversely affecting the efficacy of the chemotherapeutic agent(s). Additionally, the use of these compositions enables the administration of higher doses of the chemotherapeutic agent(s). The compositions contain particles, comprising nanoparticles, microparticles, or combinations thereof, which contain a hepatoprotective agent. The systems contain a first formulation comprising particles that contain a protective agent to the liver and a second formulation comprising a chemotherapeutic agent. The particles containing the hapatoprotective agent are short circulating particles.Type: ApplicationFiled: July 12, 2018Publication date: January 17, 2019Inventors: Joshua Reineke, Mikhail Durymanov, Anastasia Permyakova
-
Publication number: 20190015336Abstract: A pharmaceutical dosage form which comprises a lactide, glycolide or lactide-glycolide polymer, a block polymer of polyglycolide, trimethylene carbonate, poly-caprolactone, and polyethylene oxide that is combined with a peptide or protein therapeutic agent in the form of microparticles which are compressed using a pressure of 50,000 to 350,000 psi.Type: ApplicationFiled: July 10, 2018Publication date: January 17, 2019Inventors: Barry M. Libin, Jeffrey M. Liebmann, Weiliam Chen
-
Publication number: 20190015337Abstract: Embodiments of the disclosure relate generally to formulations, methods, kits, and dosage forms for improved stability of an active pharmaceutical ingredient, wherein the active ingredient comprises a compound of the formula: wherein X is N, Y is H or optionally substituted C1-C6 alkyl; R4 is morpholine optionally substituted with by C1-C6 alkyl; R7 is C1-C6 alkyl optionally substituted by one or more F; R8? is halogen; and R6 is wherein R10 is H, C1-C6 alkyl, halogen, CN or CF3; R12 is H or halogen; R13 is H, halogen or C1-C6 alkyl; and R17 is H, C1-C6 alkyl, (C1-C6 alkyl)-NH2; and, pharmaceutically acceptable salts and free bases thereof, wherein the active ingredient remains in substantially amorphous form after storage of the pharmaceutical formulation for a predetermined time and conditions.Type: ApplicationFiled: July 16, 2018Publication date: January 17, 2019Inventors: Navnit Shah, Harpreet Sandhu, Ashish Chatterji, Helen Usansky, Louis Denis, Niranjan Rao, Sarper Toker
-
Publication number: 20190015338Abstract: The present invention relates to a self-assembly preparation method of a nanocomposite material, and more particularly, relates to a self-assembly preparation method of a nanocomposite material comprising steps of: spraying a drug-containing solution onto metal aerosol nanoparticles to form a drug layer on the metal aerosol nanoparticles; and spraying a polymer-containing solution onto the metal aerosol nanoparticles, on which the drug layer is formed, to form a polymer layer on the drug layer, whereby since the method involves no liquid chemical process upon producing the metal aerosol nanoparticles, the processes are simple and can be performed even at a low temperature to suppress deformation of an organic or a drug, and the release rate of the drug, or the like can be easily controlled through metal types of metal aerosol nanoparticles, modification, and the like.Type: ApplicationFiled: November 8, 2016Publication date: January 17, 2019Inventor: Jeong Hoon BYEON
-
Publication number: 20190015339Abstract: The present invention relates to a tablet comprising candesartan or candesartan cilexetil and amlodipine or its pharmaceutically acceptable salt as active ingredients, the tablet using a particular solubilizer in order to significantly improve the stability and dissolution properties of the active ingredients. In addition, the present invention relates to a method of preparing the tablet.Type: ApplicationFiled: December 28, 2016Publication date: January 17, 2019Applicant: SHIN POONG PHARMACEUTICAL CO., LTD.Inventors: Jei-Man RYU, Woo-Ile PARK, Kyoung-Hwan KANG, Woo-Kyung KIM, Ah-Reum CHAE, Soo-Won KIM, Hyun-Woo JUNG, Jae-Young LEE
-
Publication number: 20190015340Abstract: Described herein are pharmaceutical formulations of Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one. Also disclosed are methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.Type: ApplicationFiled: September 11, 2018Publication date: January 17, 2019Inventors: Ching W. Chong, Robert Kuehl, Heow Tan, Harisha Atluri
-
Publication number: 20190015341Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.Type: ApplicationFiled: September 18, 2018Publication date: January 17, 2019Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
-
Publication number: 20190015342Abstract: Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract.Type: ApplicationFiled: September 17, 2018Publication date: January 17, 2019Applicant: COSMO TECHNOLOGIES LIMITEDInventors: Roberto VILLA, Massimo PEDRANI, Mauro AJANI, Lorenzo FOSSATI
-
Publication number: 20190015343Abstract: The invention relates to a three-dimensionally printed pharmaceutical dosage form comprising a first pharmacologically active ingredient and a second pharmacologically active ingredient; wherein the relative weight ratio of the first pharmacologically active ingredient to the second pharmacologically active ingredient in the pharmaceutical dosage form is within the range of from 10,000:1 to 1:1. The invention also relates to a process for the preparation of such pharmaceutical dosage form by three-dimensional printing, preferably by fused deposition modeling.Type: ApplicationFiled: September 18, 2018Publication date: January 17, 2019Applicant: GRÜNENTHAL GMBHInventors: Carmen STOMBERG, Klaus WENING, Marcel HAUPTS
-
Publication number: 20190015344Abstract: The invention relates to a pharmaceutical dosage form having a density below the density of gastric fluid, wherein the dosage form comprises a pharmacologically active ingredient and a cavity. The invention also relates to a process for the preparation of said dosage form comprising a three-dimensional printing step.Type: ApplicationFiled: September 18, 2018Publication date: January 17, 2019Applicant: GRÜNENTHAL GMBHInventors: Klaus WENING, Carmen STOMBERG, Marcel HAUPTS
-
Publication number: 20190015345Abstract: To provide an enteric coated tablet containing a large amount of medicinal ingredient and having sufficient impact resistance, without forming a thick enteric coating layer. The enteric coated tablet contains (A) a core tablet containing a medicinal ingredient and having a weight of 1,000 mg or more; (B) a coating layer containing a water-soluble polymer applied onto the surface of the core tablet; and (C) an enteric coating layer dissolving at pH 7 or higher which is applied onto the surface of the coating layer containing a water-soluble polymer, wherein the sum of the polymer amount of the coating layer (B) and the polymer amount of the coating layer (C) is 10 to 18 mg/cm2, the polymer amount of the coating layer (B) is 6 to 12 mg/cm2, and the polymer amount of the coating layer (C) is 3 to 6 mg/cm2.Type: ApplicationFiled: September 20, 2018Publication date: January 17, 2019Applicant: ZERIA PHARMACEUTICAL CO., LTD.Inventors: Akio Ryu, Miyako Osada
-
Publication number: 20190015346Abstract: Formulations for oral administration of water-insoluble cannabinoids are disclosed. More particularly, self-emulsifying drug delivery systems for oral administration of water-insoluble, lipophilic cannabinoids are disclosed.Type: ApplicationFiled: June 22, 2018Publication date: January 17, 2019Applicant: PHARMACANNIS LABS LLCInventor: Christopher Diorio
-
Publication number: 20190015347Abstract: A sterile pharmaceutical dosage form which comprises an ester capped lactide polymer, glycolide polymer or a lactide-glycolide copolymer hypercompressed with an active pharmaceutical ingredient wherein said sterile pharmaceutical dosage form has been sterilized with an electron beam and a method of preparing said sterile pharmaceutical dosage form.Type: ApplicationFiled: July 10, 2018Publication date: January 17, 2019Inventors: Barry M. Libin, Jeffrey M. Liebmann, Weiliam Chen
-
Publication number: 20190015348Abstract: Provided is a nanoparticle-vitreous body-based protein complex, and more particularly, to a composition for inhibiting angiogenesis which includes the complex as an active ingredient, and a composition for preventing or treating an angiogenesis-related disease or a retinal disease. When the nanoparticle-vitreous body-based protein complex according to the subject matter is locally injected into the vitreous body, the complex exhibits significantly excellent binding strength with a vascular endothelial growth factor and thus can inhibit angiogenesis, thus being easily used to prepare a therapeutic agent for preventing, alleviating, or treating retinal and choroidal angiogenesis-related diseases.Type: ApplicationFiled: July 12, 2016Publication date: January 17, 2019Applicants: SEOUL NATIONAL UNIVERSITY R & DB FOUNDATION, KOREA RESEARCH INSTITUTE OF STANDARDS AND SCIENCEInventors: Jeong Hun KIM, Dong Hyun JO, Tae Geol LEE
-
Publication number: 20190015349Abstract: Inflammatory bowel disease (IBD) is a chronic inflammatory gastrointestinal disorder that affects more than 1 million individuals in the USA. Described herein are nanoparticle mucus penetrating formulations for administration of drugs for improved mucosal distribution and tissue penetration such as in the treatment of IBD.Type: ApplicationFiled: July 16, 2018Publication date: January 17, 2019Inventors: Justin Hanes, Laura M. Ensign
-
Publication number: 20190015350Abstract: Symmetrically and asymmetrically branched homopolymers are modified at the surface level with functional groups that enable forming aggregates with a taxane, such as, paclitaxel and derivatives thereof, which are water insoluble or poorly water soluble. The aggregates are formed by interaction of a taxane and a homopolymer. Such aggregates improve drug solubility, stability, delivery and efficacy.Type: ApplicationFiled: July 22, 2018Publication date: January 17, 2019Inventors: Ray Yin, Jing Pan, Yubei Zhang, Bingsen Zhou, Yun Yen
-
Publication number: 20190015351Abstract: This disclosure relates to nanoparticles for preventing, treating and reversing atherosclerosis.Type: ApplicationFiled: July 13, 2018Publication date: January 17, 2019Inventors: Yinghui Zhong, Jia Nong, Zhicheng Wang
-
Publication number: 20190015352Abstract: Dermal and transdermal patches (also called “applicators”) for delivering treatment material. In certain aspects, a treatment patch for applying treatment material to the skin of living beings, for example, a mammal or animal, including, but not limited to human beings. In at least some embodiments, such a patch includes a main body made up of a plurality of interconnected subunit patches with open space between patches. Adjacent patches are connected with one, two, three or more connectors connected to each adjacent patch and extending between them. The connectors can be of the same size and thickness as the interconnected patches (often herein “subunit patches”). In size, the connectors can be of the same length, width, height and area as the patches. The patches can all be the same, or different patches can be used as parts of the same main body.Type: ApplicationFiled: July 5, 2018Publication date: January 17, 2019Inventor: Pendleton Brewster Wickersham
-
Publication number: 20190015353Abstract: The present invention relates to the administration of compositions comprising polyethylene glycol, for improving the general gastrointestinal health of an animal increasing growth performance and treating osteopenia, osteoporosis and other bone disorders.Type: ApplicationFiled: August 10, 2018Publication date: January 17, 2019Applicants: MIDWAY PHARMACEUTICALS, INC., BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITYInventors: Rifat PAMUKCU, Laura Rae McCABE
-
Publication number: 20190015354Abstract: A method for treating a patient having a psychiatric disorder and/or certain psychological or neurological symptoms is disclosed. The method includes administering to the patient one or more comestible units, e.g., cookies, cumulatively comprising a therapeutically effective amount of inositol, optionally at least 12,000 mg inositol.Type: ApplicationFiled: September 17, 2018Publication date: January 17, 2019Inventor: Richard Louis Price
-
Publication number: 20190015355Abstract: The current invention is a method of preventing and treating certain diseases by preventing the synthesis and/or breakdown of glycogen by the administration of an agent, guaiacol. Diseases that can be prevented and treated by the administration of guaiacol include but are not limited to glycogen storage disease type IV (GSD-IV), adult polyglucosan body disease (APBD), and Lafora disease (LD). The invention also includes methods and tools for screening for agents that prevent and treat these diseases as well as basic research, specifically in the form of cells and cell lines that produce detectable polyglucosan.Type: ApplicationFiled: January 6, 2017Publication date: January 17, 2019Applicants: The Trustees of Couumbia University in the City of New York, Hadasit Medical Research Services and Development Ltd.Inventors: Hasan Orhan AKMAN, Salvatore DIMAURO, Or KAKHLON
-
Publication number: 20190015356Abstract: Stable Phytonadione compositions for parenteral administration are provided which comprise (E) isomer of phytonadione at or greater than 97% w/w as the active ingredient, and is substantially free of (Z) isomer. Said compositions are stable, sterile, and particulate-free. Further, said compositions reduce or avoid allergic reactions to benzyl alcohol and polysorbate. In some aspects, the compositions are free or substantially free of benzyl alcohol and/or reduced amounts of polysorbate. Methods of manufacture and methods of administration also provided.Type: ApplicationFiled: July 24, 2018Publication date: January 17, 2019Inventors: Phanesh Koneru, Sreerarama Murthy Mallipeddi, Jonathan E. Sterling
-
Publication number: 20190015357Abstract: Pharmaceutical composition of memantine for administering orally which comprises a premixture comprising: i) between 74 and 85% w/w total of the premixture of a granulate of pellets comprising memantine between 10 and 15% w/w total of the premixture; coated by first coating of polyvinylpyrrolidone and a second coating comprising between 80 and 95% w/w total of the coating of cationic copolymer of dimethylaminoethyl methacrylate, butyl methacrylate and methyl methacrylate and between 5 and 20% w/w total of the coating of magnesium stearate; ii) between 4 and 7% w/w total of the premixture of sucralose; iii) between 11 and 19% w/w total of the premixture of essences. All the components have a particle size smaller than 710 microns. The composition can be a suspension, a powder for preparing a suspension or an oral disintegrating tablet. It can also be used to be administered through a nasogastric tube.Type: ApplicationFiled: December 23, 2015Publication date: January 17, 2019Inventor: Mario Atilio Los
-
Publication number: 20190015358Abstract: Provided herein are compositions useful for treating inflammation in a subject and methods of decreasing inflammation in the skin, mucosa, and/or eye of a subject comprising applying a pharmaceutical composition that includes an NO-releasing compound to the skin, mucosa, and/or eye of the subject in an amount sufficient to decrease inflammation.Type: ApplicationFiled: March 2, 2017Publication date: January 17, 2019Inventors: Nathan Stasko, Ryan Doxey, Kimberly McHale, Stanley J. Hollenbach
-
Publication number: 20190015359Abstract: There is provided a patch to enhance locally fat metabolism, using a thermoplastic elastomer gel composition including capsaicin, which is applied to the skin surface, comprises: a skin adhering layer formed of the thermoplastic elastomer (TPE) gel including capsaicin, the skin adhering layer having a top surface and a bottom surface; a base layer secured to the bottom surface of the skin adhering layer, to support for the patch; and a removable paper/film layer secured to the top surface of the skin adhering layer, to protect the skin adhering layer prior to use, wherein the skin adhering layer comprises: 3˜12 wt % of styrene ethylene butylene styrene (SEBS) or styrene ethylene ethylene propylene styrene (SEEPS), 44˜53 wt % of an adhesive agent; 44˜53 wt % of mineral oil, and 0.001˜0.009 wt % of capsaicin. Capsaicin included in the TPE gel derives heat generation and fat breakdown, to help attain fat loss in the area where the patch is applied.Type: ApplicationFiled: July 13, 2017Publication date: January 17, 2019Inventors: Kyu-Hak CHO, Seung-Wook YOON
-
Publication number: 20190015360Abstract: There is herein provided valproic acid, or a pharmaceutically acceptable salt thereof, for use in treating or preventing a pathological condition associated with excess fibrin deposition and/or thrombus formation, wherein said treatment comprises treating a patient with valproic acid, or a pharmaceutically acceptable salt thereof, in a specific manner, and formulations for use or designed for use in such treatments.Type: ApplicationFiled: September 19, 2018Publication date: January 17, 2019Inventors: Sverker Jern, Jonas Faijerson Saljo, Niklas Bergh